Campath-1H use in pediatric renal transplantation

American Journal of Transplantation

Volumn 5, Issue 6, 2005, Pages 1569-1573

  Bartosh, Sharon M ^a   Knechtle, Stuart J ^a   Sollinger, Hans W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Humanized antibodies; Kidney transplantation; Pediatric

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CALCINEURIN INHIBITOR; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENT FACTOR H; COTRIMOXAZOLE; CYCLOSPORIN; HYDROCORTISONE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CADAVER KIDNEY; CASE REPORT; CHILD; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GLOMERULOSCLEROSIS; HEMOLYTIC UREMIC SYNDROME; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MAINTENANCE THERAPY; MALE; MEDULLARY SPONGE KIDNEY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENCE RISK; SINGLE DRUG DOSE;

EID: 20544434671     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00879.x     Document Type: Article

References (13)

1. Calne R, Friend P, Moffatt S et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701-1702.
2. Leventhal JR, Gallon L, Kaufman DB, Stuart J, Koffron AJ, Fryer JP. Alemtuzumab (Campath 1-H) facilitates prednisone free immunosuppression (IP) in kidney transplant recipients (abstract). Am J Transplant 2003; 3: 310.
3. Knechtle SJ. Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatr Transplant 2004; 8: 106-112.
4. Knechtle SJ, Pirsch JD, Voss BJ et al. Campath-1H in patients with delayed graft function: Reduced rejection and improved graft survival [abstract]. Am J Transplant 2004; 4: 404.
5. Ciancio G, Burke GW, Gaynor JJ et al. The use of Campath-1H as induction therapy in renal transplantation: Preliminary results [abstract]. Am J Transplant 2004; 4: 404.
6. Watson CJ, Firth J, Bradley J et al. Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up (abstract). Am J Transplant 2004; 4: 404.
7. Tzakis AG, Kato T, Nishida S et al. Preliminary experience with Campath 1H (C1H) in intestinal and liver transplantation. Transplantation, 2003; 75: 1227-1231.
8. Kirk AD, Hale DA, Mannon RB et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120-129.
9. Knechtle SJ, Pirsch JD, H Fechner J Jr et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 643-645.
10. Caspar HB, Amrolia P, Hassan A et al. Non-myeloablative stem cell transplantation for congenital immunodeficiencies. Recent Results Cancer Res 2002; 159: 134-142.
11. Seikaly MG. Recurrence of primary disease in children after renal transplantation: an evidence-based update. Pediatr Transplant 2004; 8: 113-119.
12. Loirat C, Niaudet P. The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003; 18: 1095-1101.
13. Isaacs JD, Greer S, Sharma S et al. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced Lymphopenia. Arthritis Rheum 2001; 44: 1998-2008.